Last reviewed · How we verify

STW5 (Iberogast, BAY98-7411) — Competitive Intelligence Brief

STW5 (Iberogast, BAY98-7411) (STW5 (Iberogast, BAY98-7411)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal combination product. Area: Gastroenterology.

phase 3 Herbal combination product Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

STW5 (Iberogast, BAY98-7411) (STW5 (Iberogast, BAY98-7411)) — Bayer. STW5 is a herbal combination product that modulates gastric motility and secretion to improve digestive function and reduce functional gastrointestinal symptoms.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
STW5 (Iberogast, BAY98-7411) TARGET STW5 (Iberogast, BAY98-7411) Bayer phase 3 Herbal combination product
Baracross Tablet Baracross Tablet Daewoong Pharmaceutical Co. LTD. marketed Herbal combination product
STW 5-II STW 5-II Universitaire Ziekenhuizen KU Leuven marketed Herbal combination product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal combination product class)

  1. Bayer · 1 drug in this class
  2. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
  3. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). STW5 (Iberogast, BAY98-7411) — Competitive Intelligence Brief. https://druglandscape.com/ci/stw5-iberogast-bay98-7411. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: